Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Bacteria or actinomycetales
Reexamination Certificate
2005-06-14
2005-06-14
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Bacteria or actinomycetales
C424S093450, C424S408000, C424S439000, C424S450000
Reexamination Certificate
active
06905679
ABSTRACT:
The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells byGiardia intestinalis, for the preparation of an ingestable carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut byGiardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestable carrier, such as a food or pharmaceutical composition containing such supernatant or the microorganisms.
REFERENCES:
patent: 5603930 (1997-02-01), Brassart et al.
patent: 0 577 904 (1994-01-01), None
patent: WO 96/29083 (1996-09-01), None
patent: WO 97/35596 (1997-10-01), None
patent: WO 01/30365 (2001-05-01), None
Thompson et al. article entitled “Nomenclature and Genetic Groupings ofGiardiaInfecting Mammals”Parasitology Today, vol. 16, No. 5, 2000, pp. 210-213.
Rasic et al. article entitled “Bifidobacteria and Their Role” 1983, pp. 86-101.
Reiner et al. article entitled “Human Milk KillsGiardia lambliaby Generating Toxic Lipolytic Products”The Journal of Infectious Diseases, vol. 154, No. 5, Nov. 1986, pp. 835-832.
Chavez et al., “Giardia lamblia; In Vitro Cytopathic Effect of Human Isolates” Experimental Parasitology 80, 1995, pp. 133-138.
Buret et al., “Pathophysiology of Small Intestinal Malabsorption in Gerbils Infected WithGiardia Iamblia,” Gastroenterology 103, 1992, pp. 506-513.
Roberts-Thomson, et al., “Giardiasis in the Mouse: An Animal Model” Gastroenterology 71, 1976, pp. 57-61.
Aley et al., “Specialized Surface Adaptations ofGiardia lamblia” Infectious Agents and Disease, 4, 1995, pp. 161-166.
Muller et al., “Serological Analysis of Antigenic Heterogeneity ofGiardia lambliaVariant Surface Proteins” Infection and Immunity, 64, 1996, pp. 1385-1390.
Nash et al., “Giardia lamblia:Identification and Characterization of a Variant-Specific Surface Protein Gene Family” J. Euk. Microbiol., 42, 1995, pp. 604-609.
Gillin et al., “Cell Biology of the Primitive EukaryoteGiardia Lamblia” Annu. Rev. Microbiol. 50, 1996, pp. 679-705.
Katelaris et al., “Activity of metronidazole, azithromycin and three benzimidazoles onGiardia lambliagrowth and attachment to a human intestinal cell line” Altment Pharmacol. Ther. 8, 1994, pp. 187-192.
Perez Pablo
Schiffrin Eduardo
Bell Boyd & Lloyd LLC
Lilling Herbert J.
Nestec S.A.
LandOfFree
Lactic acid bacteria for the treatment and/or prophylaxis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactic acid bacteria for the treatment and/or prophylaxis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactic acid bacteria for the treatment and/or prophylaxis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470941